NCT05539794Recruiting
Exercise in Adolescents With Cancer
Exercise Intervention for Adolescents With Cancer (EXERCADOL): A Randomized Controlled Trial
Source: ClinicalTrials.gov · Last updated 22 Jul 2026
Brief summary (registry, in English)
The investigators will study the effects of an supevised exercise intervention along the duration of intensive treatment (neoadjuvant \[solid tumours\]/intense chemotherapy \[leukemias\], expected median duration 5-6 months) on several health-related variables. Participants will be recruited from 4 hospitals in Madrid (Spain). Inclusion criteria: male/female aged 12-19 years, newly diagnosed--or relapse of-- a malignant extracranial tumour; not having received any type of therapy--except surgery--at the time of diagnosis; adequate health status (Karnofsky/Eastern Cooperative Oncology Group scale score ≥50/≤2); to understand Spanish language and to provide written informed consent. The investigators will recruit ≥136 participants and conduct a randomised controlled trial. The intervention group will follow a supervised concurrent exercise program from the start to the end of intensive treatment. The exercise intervention will be performed in the hospital gymnasium or in the patients' ward (during neutropenic phases), and will also include supervised online sessions. Additionally, the intervention group will perform include inspiratory muscle training. The following outcomes will be assessed at baseline (diagnosis), end of treatment, and at 3-month follow-up in all participants: echocardiography-determined left ventricular function (primary outcome); and other echocardiography-determined variables, cardiac biomarkers, blood pressure, blood lipids, body composition, physical activity levels, energy intake, cardiorespiratory fitness, muscle strength, functional mobility, health-related quality of life, cancer-related fatigue, clinical variables, and potential biological underpinnings of exercise multisystemic benefits (metabolic and inflammatory markers, plasma proteome, gut microbiome, and immune function).
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 136 (estimated)
- First submitted
- 18 Apr 2022
- Start date
- 15 Apr 2022
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- Universidad Europea de Madrid
- Diseases
- Childhood cancers
- NCT number
- NCT05539794
What you commit to
- Study type: Interventional
- Planned participants: 136
- From 15 Apr 2022 to the primary completion date, 31 Dec 2026
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Comorbidity/acute condition contraindicating exercise practice
Other
- Life expectancy \<3 months
Who the study is looking for
- Newly diagnosed with a malignant extracranial tumour
- Not having received any therapy--except surgery--at diagnosis
- Adequate health status (Karnofsky/Eastern Cooperative Oncology Group scale score ≥50/2)
- To understand Spanish language and provide written informed consent.
Age in the registry: 12 years to 19 years · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| UEM Coordinator of this site? Confirm its status | Madrid | Spain | Recruiting |
| Universidad Europea de Madrid Coordinator of this site? Confirm its status | Villaviciosa de Odón | Spain | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.